217 related articles for article (PubMed ID: 9920028)
1. Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies.
Sobao Y; Tsuchiya N; Takiguchi M; Tokunaga K
Arthritis Rheum; 1999 Jan; 42(1):175-81. PubMed ID: 9920028
[TBL] [Abstract][Full Text] [Related]
2. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain.
el-Zaatari FA; Sams KC; Taurog JD
J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355
[TBL] [Abstract][Full Text] [Related]
3. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703.
Villadangos JA; Galocha B; García F; Albar JP; López de Castro JA
Eur J Immunol; 1995 Aug; 25(8):2370-7. PubMed ID: 7664799
[TBL] [Abstract][Full Text] [Related]
4. Several HLA alleles share overlapping peptide specificities.
Sidney J; del Guercio MF; Southwood S; Engelhard VH; Appella E; Rammensee HG; Falk K; Rötzschke O; Takiguchi M; Kubo RT
J Immunol; 1995 Jan; 154(1):247-59. PubMed ID: 7527812
[TBL] [Abstract][Full Text] [Related]
5. B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA-B27 subtypes not associated to spondyloarthritis.
Gómez P; Montserrat V; Marcilla M; Paradela A; de Castro JA
Eur J Immunol; 2006 Jul; 36(7):1867-81. PubMed ID: 16783853
[TBL] [Abstract][Full Text] [Related]
6. HLA-B27: a registry of constitutive peptide ligands.
Lopez de Castro JA; Alvarez I; Marcilla M; Paradela A; Ramos M; Sesma L; Vázquez M
Tissue Antigens; 2004 May; 63(5):424-45. PubMed ID: 15104674
[TBL] [Abstract][Full Text] [Related]
7. Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis.
Lamas JR; Paradela A; Roncal F; López de Castro JA
Arthritis Rheum; 1999 Sep; 42(9):1975-85. PubMed ID: 10513815
[TBL] [Abstract][Full Text] [Related]
8. Extended repertoire of permissible peptide ligands for HLA-B*2702.
Raghavan M; Lebrón JA; Johnson JL; Bjorkman PJ
Protein Sci; 1996 Oct; 5(10):2080-8. PubMed ID: 8897608
[TBL] [Abstract][Full Text] [Related]
9. Peptide binding to empty HLA-B27 molecules of viable human cells.
Benjamin RJ; Madrigal JA; Parham P
Nature; 1991 May; 351(6321):74-7. PubMed ID: 2027387
[TBL] [Abstract][Full Text] [Related]
10. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules.
Sidney J; Southwood S; del Guercio MF; Grey HM; Chesnut RW; Kubo RT; Sette A
J Immunol; 1996 Oct; 157(8):3480-90. PubMed ID: 8871647
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705.
Jones MA; Hislop AD; Snaith JS
Org Biomol Chem; 2006 Oct; 4(20):3769-77. PubMed ID: 17024283
[TBL] [Abstract][Full Text] [Related]
12. Testing the importance of each residue in a HLA-B27-binding peptide using monoclonal antibodies.
Fukazawa T; Wang J; Huang F; Wen J; Tyan D; Williams KM; Raybourne RB; Yu DT
J Immunol; 1994 Feb; 152(3):1190-6. PubMed ID: 8301123
[TBL] [Abstract][Full Text] [Related]
13. Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition.
Villadangos JA; Galocha B; López D; Calvo V; López de Castro JA
J Immunol; 1992 Jul; 149(2):505-10. PubMed ID: 1378067
[TBL] [Abstract][Full Text] [Related]
14. The amino acid at position 97 is involved in folding and surface expression of HLA-B27.
Blanco-Gelaz MA; Suárez-Alvarez B; González S; López-Vázquez A; Martínez-Borra J; López-Larrea C
Int Immunol; 2006 Jan; 18(1):211-20. PubMed ID: 16361312
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody that recognizes HLA-B27 in the context of peptides.
Wang J; Yu DT; Fukazawa T; Kellner H; Wen J; Cheng XK; Roth G; Williams KM; Raybourne RB
J Immunol; 1994 Feb; 152(3):1197-205. PubMed ID: 8301124
[TBL] [Abstract][Full Text] [Related]
16. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies.
Boisgérault F; Tieng V; Stolzenberg MC; Dulphy N; Khalil I; Tamouza R; Charron D; Toubert A
J Clin Invest; 1996 Dec; 98(12):2764-70. PubMed ID: 8981922
[TBL] [Abstract][Full Text] [Related]
17. High T cell epitope sharing between two HLA-B27 subtypes (B*2705 and B*2709) differentially associated to ankylosing spondylitis.
García-Peydró M; Martí M; López de Castro JA
J Immunol; 1999 Aug; 163(4):2299-305. PubMed ID: 10438975
[TBL] [Abstract][Full Text] [Related]
18. [Subtypes of the HLA-B27 molecule and association with spondylarthropathies].
Toubert A; Tieng V; Boisgérault F; Dulphy N; Tamouza R; Charron D
Ann Med Interne (Paris); 1998 Apr; 149(3):145-8. PubMed ID: 11490536
[TBL] [Abstract][Full Text] [Related]
19. Exploring myelin basic protein for HLA class I-binding sequences.
Tanigaki N; Fruci D; Groome N; Butler RH; Londei M; Tosi R
Eur J Immunol; 1994 Sep; 24(9):2196-202. PubMed ID: 7522167
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity.
Barber LD; Percival L; Arnett KL; Gumperz JE; Chen L; Parham P
J Immunol; 1997 Feb; 158(4):1660-9. PubMed ID: 9029102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
